First-line Anti-GD2 Therapy Combined With Consolidation Chemotherapy in 3 Patients With Newly Diagnosed Metastatic Ewing Sarcoma or Ewing-like Sarcoma

Despite multimodal therapy, the prognosis of patients with metastatic Ewing sarcoma (ES) remains poor, with new treatments urgently needed. The disialoganglioside GD2, a well-established tumor-associated antigen, is expressed in 40% to 90% of ES cells, making it a suitable therapeutic target. Here w...

Descripción completa

Detalles Bibliográficos
Autores principales: Spasov, Neofit J., Dombrowski, Frank, Lode, Holger N., Spasova, Mariya, Ivanova, Liliya, Mumdjiev, Ivan, Burnusuzov, Hassan, Siebert, Nikolai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Online Articles: Clinical and Laboratory Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/
https://www.ncbi.nlm.nih.gov/pubmed/35622995
http://dx.doi.org/10.1097/MPH.0000000000002488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323561/
https://www.ncbi.nlm.nih.gov/pubmed/35622995
http://dx.doi.org/10.1097/MPH.0000000000002488

Ejemplares similares